A phase I, first-in-human study of MGD006/S80880 (CD123 x CD3 DART) in AML/MDS.
Norbert Vey(Centre de Recherche en Cancérologie de Marseille), John F. DiPersio(Washington University in St. Louis), Matteo Giovanni Carrabba(Vita-Salute San Raffaele University), Michele Shannon(MacroGenics (United States)), Fabio Ciceri(Vita-Salute San Raffaele University), Matthew C. Foster(University of North Carolina at Chapel Hill), Gerwin Huls(University Medical Center Groningen), Jon M. Wigginton(Bristol-Myers Squibb (United States)), H. Jean Khoury(Emory University), John E. Godwin(Providence Portland Medical Center), David A. Rizzieri(Duke University), Giovanni Martinelli(University of Bologna), Max S. Topp(Universitätsklinikum Würzburg), Geoffrey L. Uy(Memorial Sloan Kettering Cancer Center), Antje Wegener(Servier (France)), Jichao Sun(MacroGenics (United States)), Jan Davidson‐Moncada(MacroGenics (United States))
Cited by 8
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k